Mitralign to Provide Update on Transcatheter Tricuspid Repair at TCT 2015
SCOUT study for
percutaneous tricuspid repair to begin enrollment in Q4
TEWKSBURY, Mass., Mitralign will present updates on its mitral and tricuspid valve repair platform at the Transcatheter Cardiovascular Therapeutics (TCT) conference Oct 11-15 in San Francisco. As a part of conference updates, the company will also provide details on the SCOUT study utilizing its TriAlignTM Tricuspid Percutaneous Valve Annuloplasty System as part of an Early Feasibility Investigational Device Exemption (IDE) approved by the FDA. The SCOUT study will be a multi-center U.S. study and will commence patient enrollment in Q4 2015.
“We are excited to begin formal clinical investigation in the United States with the TriAlign System to reinforce our position as the most promising percutaneous tricuspid repair solution,” said Rick Geoffrion, chief executive officer of Mitralign.
Mitralign is the only company to provide a direct percutaneous annuloplasty system designed to treat both functional mitral regurgitation (FMR) and tricuspid regurgitation (FTR) with the continued advancement of its core technology. Both the Mitralign and TriAlign Systems feature a customizable therapy solution in concert with an extremely small footprint in the native anatomy. Neither the Mitralign nor the TriAlign Systems are currently approved for sale or distribution.
“The patient population suffering from tricuspid regurgitation continues to need an approved transcatheter repair solution and early experience with the TriAlign System shows encouraging results,” commented Rebecca Hahn, MD, Director of Interventional Echocardiography, Columbia University Medical Center / New York Medical Center / New York Presbyterian Hospital and Principal Investigator for the SCOUT study. “Percutaneous repair for tricuspid regurgitation is the next horizon in valve therapy.”
Updates on Mitralign’s percutaneous solutions will be available in their booth, 2233, and also during a Mitralign sponsored symposium, A Frontline Platform for Transcatheter Mitral and Tricuspid Repair, on October 13 from 1-2 PM in Moscone South, Lower Level, Exhibit Hall Presentation Theater 3. The faculty includes Rebecca T. Hahn, MD, Azeem Latib, MD, Scott Lim, MD, Neil E. Moat, MD and Joachim Schofer, MD.
Additional data on the Mitralign and TriAlign Systems will be presented at the ICI conference from December 13-15 in Tel Aviv, Israel, at the Joint Interventional Meeting (JIM) from February 11-13, 2016 in Milan, Italy and at the American College of Cardiology (ACC) Scientific Sessions from April 2-4, 2016 in Chicago.
Source: Mitralign Inc.
Comments